Agency IQ
AUGUST 2, 2024
Positive August 2024 Eurneffy (epinephrine) Ars Pharmaceuticals Irl Limited Positive August 2024 MResvia (Respiratory Syncytial Virus mRNA vaccine) Moderna Biotech Spain S.L. Positive August 2024 Balversa (erdafitinib) Janssen-Cilag International N.V.
The Pharma Data
JUNE 7, 2022
Those taking up this offer will be required to hold the Shares or the corresponding FCPE units for a period of approximately five years, i.e. until 31 May 2027, except upon the occurrence of an early release event provided for under Article R. The voting rights attached to the subscribed Shares will be exercised directly by the employees.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
JUNE 26, 2021
To date, the company has already notably: reduced GHG emission from its activities by 27% since 2015; designed a new entirely recyclable cardboard packaging for vaccines, which replaces aluminum and PVC blisters; reused, recycled, or recovered 73% of its waste; and reduced by 22% its water withdrawal from 2015 to 2020.
Agency IQ
OCTOBER 20, 2023
BSUFA III aimed to address biosimilar development challenges via a new regulatory science pilot program In the latest reauthorization of the Biosimilar User Fee Act (BSUFA III), FDA committed to a variety of activities for fiscal years 2023 through 2027.
Advarra
JUNE 13, 2023
Research in gene therapies and genetically engineered drugs and vaccines are growing exponentially, and will only continue to become more popular. between 2020-2027. When treatments involve recombinant or synthetic nucleic acids, including messenger RNA (mRNA) or viral vector vaccines, additional IBC oversight is necessary.
The Pharma Data
DECEMBER 14, 2020
A product called DENARASE, which is used in gene and cell therapy, but is also required for production of certain types of vaccines, was the biggest driver of growth in 2020. Therefore, significant momentum came from vaccine development and production in 2020. The kit can be used to detect DENARASE residues.
The Pharma Data
DECEMBER 30, 2020
Elsewhere across the globe: Arcturus Therapeutics – San Diego-based Arcturus Therapeutics received approval from the Singapore Health Sciences Authority to proceed with a Phase II clinical study of its vaccine candidate ARCT-021 against COVID-19. billion by 2027.
Expert insights. Personalized for you.
40 
Let's personalize your content